Close
ACHEMA MIDDLE EAST 2026

CRO Market Outlook: Growth Potential & Regulatory Obstacles

As per insights, the global clinical research organization (CRO) market is projected to achieve a value of $139.56 billion by 2033. The market is...

Biotech M&A Is Set For Rebound With Billion-Dollar Deals

2022 was an unremarkable year for biotech mergers and acquisitions (M&A) as the industry experienced a decline in both the number and value of...

Centogene, Lifera Join Forces To Improve Multiomic Testing

Centogene, a life science company based in Germany that specializes in rare and neurodegenerative diseases, and Lifera, a biopharmaceutical company owned by the Public...

US – China Trade In Pharmaceuticals Soars In Recent Years

The US-China trade in pharmaceuticals has shifted due to the trade war and the pandemic. While some sectors have seen a decline, pharmaceutical trade...

ACHEMA 2024: Shaping the future of the process industries

From 10 to 14 June 2024, ACHEMA will once again be the place to go for the entire range of technologies and services for...

New Guidelines: Medicare To Directly Negotiate Drug Prices

The Biden administration has issued new guidelines for its program that enables Medicare to directly negotiate drug prices with manufacturers. The updated guidelines provide...

Swiss Pharma Sector In EU Negotiations- Stakes Are Sky High

In a recent development, Switzerland may very well lose out as a manufacturing location if its differences with the European Union are not sorted...

Subscribe Our Newsletter

White Papers

The Future of Digital Health

The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....

Five Best Practices to Deliver Exceptional Multichannel Experiences

A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...

The Impact and Use of Social Media in Pharmacovigilance

Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...